Irritable bowel syndrome: Basis of clinical management strategies

Journal of Clinical Gastroenterology

Volumn 35, Issue 1 SUPPL., 2002, Pages

  Rosemore, J G ^a   Lacy, Brian E ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Abdominal pain; Constipation; Diarrhea; IBS

Indexed keywords

ANTIDIARRHEAL AGENT; ANTINOCICEPTIVE AGENT; ATROPINE PLUS DIPHENOXYLATE; CARBAMAZEPINE; CHARCOAL; CHLORDIAZEPOXIDE PLUS CLIDINIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; DESIPRAMINE; DICYCLOVERINE; DONNATAL; EQUALACTIN; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; ISPAGULA; LACTULOSE; LOPERAMIDE; METHYLCELLULOSE; OPIATE; OSMOTIC AGENT; PARACETAMOL; PAROXETINE; POLYCARBOPHIL; SCOPOLAMINE METHYL BROMIDE; SERTRALINE; SIMETHICONE; SPASMOLYTIC AGENT; TEGASEROD; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; CONFERENCE PAPER; CONSTIPATION; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DIET; FIBER; HUMAN; IRRITABLE COLON; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; DIET THERAPY; DIETARY FIBER; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTIDIARRHEALS; COLONIC DISEASES, FUNCTIONAL; COMPLEMENTARY THERAPIES; DIETARY FIBER; HUMANS; PARASYMPATHOLYTICS; PATIENT SATISFACTION; QUALITY OF LIFE; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 0036083863     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200207001-00008     Document Type: Conference Paper

References (46)

1. Problems and challenges in the design of irritable bowel syndrome clinical trials: Experience from published trials
2. Wheat fibre and irritable bowel syndrome: A controlled trial
3. Mechanisms of action of dietary fibre in the human colon
4. Effect of wheat bran on weight of stool and gastrointestinal transit time: A meta-analysis
5. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
6. Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: Correlation of symptom relief with whole gut transit time and stool weight
7. Bran and irritable bowel syndrome: Time for reappraisal
8. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
9. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea
10. Controlled treatment trials in the irritable bowel syndrome: A critique
11. Meta-analysis of smooth muscle relaxers in the treatment of irritable bowel syndrome
12. The irritable bowel syndrome (IBS): Relationship of disorders in the transit of a single solid meal to symptom patterns
13. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)
14. Loperamide: Studies on its mechanism of action
15. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency
16. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome
17. Loperamide in treatment of irritable bowel syndrome: A double-blind placebo controlled study
18. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist
19. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist
20. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
21. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
22. 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
23. Titration regimen indicates partial 5-HT agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome
24. Tegaserod accelerates orocecal transit in patients with constipation predominant irritable bowel syndrome
25. NT-3 improves functional constipation
26. Serotonin: Synthesis and release from the myenteric plexus of the mouse intestine
27. Serotonin: The neurotransmitter for the 90's
28. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel
29. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5-HT3 receptor antagonist in patients with irritable bowel syndrome
30. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
31. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine 4 receptor agonist
32. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit constipation
33. Serotonin 5HT4 receptors mediate the R093877-induced changes in contractile patterns in the canine colon
34. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers
35. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
36. Tolerance for rectosigmoid distention in irritable bowel syndrome
37. Regional cerebral activity in normal and pathologic perception of visceral pain
38. Irritable bowel syndrome. A technical review for practice guideline development
39. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome
40. Treatment of irritable bowel syndrome with chinese herbal medicine, a randomized controlled trial
41. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome
42. Hypnotherapy and therapeutic audiotape: Effective in previously unsuccessfully treated irritable bowel syndrome?
43. Hypnotherapy in severe irritable syndrome: Further experience
44. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in a rabbit and guinea pig
45. Peppermint oil for irritable bowel syndrome: A critical review and meta-analysis
46. The role of acupuncture in the treatment of irritable bowel syndrome: A pilot study